Zinnat®
cefuroxime axetil

gsk

Bacterial skin and soft tissues infections (SSTI) are one of the most common infections among different age groups[1]

Bacterial skin and soft tissue infections:

- Approximately 70% to 75% of all cases are managed in the outpatient setting[2]
- Gram-positive bacteria are the most frequently isolated pathogens with a predominance of *Staphylococcus aureus* and *Streptococcus pyogenes*[1]

IDSA 2014 Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections[3]:

- State that the clinical evaluation of patients with SSTI aims to establish the cause and severity of infection and must take into account pathogen-specific and local antibiotic resistance patterns

Cefuroxime axetil in SSTI

- Good coverage of pathogens relevant in dermatology such as methicillin susceptible *S. aureus* and beta hemolytic streptococci*[4,5]
- Established clinical and bacteriological efficacy in treating SSTI in historical clinical trials in adults and children[6-9]

Significantly more effective than cephalexin in mild to moderate infections of skin and skin structure[8]



#cure + improvement
**cure + presumed cure

Comparable efficacy to cefadroxil in resolving SSTIs in children[9]



Zinnat®
cefuroxime axetil

*Considerable variability exists in susceptibility patterns to cefuroxime. These will vary with time and geography, always refer to local susceptibility data before prescribing

Dosage and Administration[4]

The usual course of therapy is seven days (range five to ten days)

Tablets:

Cefuroxime axetil tablets should be taken after food for optimum absorption.
Adults and children *(≥40 kg):* Most infections: 250 mg twice daily
Children *(<40 kg):* Most infections: 15 mg/kg twice daily to a maximum of 250 mg twice daily.

Suspension:

For optimal absorption cefuroxime axetil suspension should be taken with food.
Adults and children *(≥40 kg):* Dosage as for Tablets
Children *(<40 kg):* The usual dose of Zinnat Suspension is 10 mg/kg (a maximum of 125 mg) to 15 mg/kg (a maximum of 250 mg) twice daily depending on the severity and type of infection and the weight and age of the child.

Main Zinnat (cefuroxime axetil) safety information[4]

- Contraindicated in patients with known hypersensitivity to cephalosporin antibiotics, and special care must be taken in patients with previous allergic reaction to beta lactams
- Gastrointestinal disturbances are common
- Prolonged use may result in overgrowth of non susceptible organisms

GlaxoSmithKline. 25 Basel street,
P.O. Box 10283, Petach-Tikva 4900202 Israel,
Tel: 03-9297100.
Medical information service: il.medinfo@gsk.com
Adverse events reporting service: il.safety@gsk.com,
Tel: 03-9297100

ל-PI המלא נא ללחוץ כאן

REFERENCES
1. Tognetti L *et al.* Bacterial skin and soft tissue infections: review of the epidemiology, microbiology, aetiopathogenesis and treatment. A collaboration between dermatologists and infectivologists. *J Eur Acad Dermatol Venereol.* 2012;26(8):931-41.
2. Ki V & Rotstein C. Bacterial skin and soft tissue infections in adults: A review of their epidemiology, pathogenesis, diagnosis, treatment and site of care. *Can J Infect Dis Med Microbiol.* 2008;19(2):173-84.
3. Stevens DL *et al.* Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America 2014. *Clin Infect Dis.* 2014;59(2):e10-52.
4. Zinnat MOH approved PI.
5. Sunderkötter C *et al.* Antimicrobial therapy in dermatology. *J Dtsch Dermatol Ges.* 2006;4(1):10-27.
6. Parish LC *et al.* Cefuroxime axetil in the treatment of cutaneous infections. *Int J Dermatol.* 1987;26(6):389-93.
7. Bucko AD *et al.* Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400 mg BID with either cefuroxime 250 mg BID or cefadroxil 500 mg BID for the treatment of uncomplicated skin and skin-structure infections. *Clin Ther.* 2002;24(7):1134-47.
8. Gooch WM *et al.* Clinical comparison of cefuroxime axetil, cephalexin and cefadroxil in the treatment of patients with primary infections of the skin or skin structures. *Dermatologica.* 1991;183(1):36-43.
9. Jacobs RF *et al.* Evaluation of cefuroxime axetil and cefadroxil suspensions for treatment of pediatric skin infections. *Antimicrob Agents Chemother.* 1992;36(8):1614-8.

*The image shown is for representational purposes only

IL/CFA/0002/16 Date of Preparation: August 2016